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jects. Mean annual costs were $18,630 (SD$40,365) and $4510
(SD$11,185) among those with and without renal disease
(p < 0.001). Subjects with renal disease had 13.03 (SD11.50)
ofﬁce visits and 0.46 (SD0.85) hospitalizations (average length of
stay of 8.63 days (SD14.60)) per year compared to 6.50 (SD7.31),
0.09 (SD0.31) and 3.63 days (SD10.36) in those without renal
disease (p < 0.001, all measures). Among subjects with renal
disease, 398 (54%), 175 (23%), and 172 (23%) were classiﬁed
with mild, moderate, and severe disease. Annual total health care
costs were $10,888 (SD$21,676), $13,692 (SD$18,114) and
$41,570 (SD$70,502) among these subjects (p < 0.001). A GLM
model adjusting for age, gender, rate of gout ﬂares, use of allopu-
rinol and Charlson comorbidity score indicated that costs were
1.89, 2.17, and 4.91 times greater among subject with mild,
moderate and severe renal impairment compared to those with no
renal disease. Subjectswithmild,moderate, and severe disease had
annual hospitalization rates of 0.25 (SD0.50); 0.58 (SD0.99); and
0.83 (SD1.16) (p < 0.001). CONCLUSION: Health care expen-
ditures and utilization among subjects with incident gout is sub-
stantially higher among those with renal disease, increasing
substantially with severity. Better management may result in
reduction in health care cost and resource utilization.
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OBJECTIVE: There are limited data on the economic impact of
mood disorders among patients with diabetic neuropathy (DN).
This study examines factors associated with health care costs
among elderly DN patients with or without depression/anxiety
(DA). METHODS: Using a retrospective cohort design and
administrative claims data, we assessed the predictors of total
health care costs over a one-year follow-up period for over-age-65
patients with 1+ diagnosis of DN. The index date was deﬁned as
the ﬁrst observed medical claim with a diagnosis for DN in 2005.
Patients with continuous eligibility for 12 months prior to and
following the index date were included. Two cohorts of patients
were constructed for individuals with DA (DN-DA) or without
(DN-only).Multivariate linear regressionwas performed to assess
whether DN-DA patients have higher health care costs than
DN-only patients, controlling for demographic and clinical char-
acteristics (diabetes-related comorbidities and treatment regimen
for diabetes observed within 12 months prior to index date).
RESULTS: We identiﬁed 16,831 DN-only patients, and 1699
DN-DA patients. The DN-only and DN-DA groups were similar
by age (75.6 vs 75.4, p = 0.44), but DN-DA patients were more
likely to be female (56% vs. 47%, p < 0.01). DN-DA patients had
higher prevalence of diabetes-related comorbidities for cardiovas-
cular disease, nephropathy, neuropathy, obesity, and hypoglyce-
mic events than DN-only patients (all p < 0.01). Controlling for
differences in demographic and clinical characteristics, DN-DA
patients had $9785 (p < 0.01) higher total health care costs than
patients with DN-only. Factors associated with increased costs
included insurance type, geographical region, diabetes-related
comorbidities, and insulin therapy. CONCLUSION: These ﬁnd-
ings indicate that the health care costs were signiﬁcantly higher for
DN patients with depression/anxiety relative to those without
these mood disorders.
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OBJECTIVE: Diabetic neuropathy (DN) is one of the most
common complications associated with diabetes. Other diabetes-
related complications include depression, cardiovascular disease,
stroke, renal complications, skin problems, visual impairment,
and amputation. This study assesses the prevalence of other
diabetes-related complications and its marginal contribution on
medical charges among DN patients. METHODS: Commercially
insured patients aged 18–64 with at least 1 claim of DN anytime
between July 2004 and June 2005 (Year 1) enrolled in a large
health plan were selected. A demographically-matched control
cohort of patients with diabetes was constructed via propensity
scoring with a 10:1 ratio to DN cohort. Both DN patients and
controls had 12 months of continuous enrollment in both Year 1
and Year 2 (July 2005-June 2006). The prevalence of other
diabetes-associated complications was compared between DN
patients and controls. Using multivariate regressions, we exam-
ined the marginal contribution of1 other diabetes-related com-
plications on Year 2 medical charges for both cohorts controlling
for comorbidities. We also assessed the impact of DN on medical
charges.RESULTS: Fewer DN patients (11% out of 8655) had no
other diabetes-related complications than controls (24% out of
86,550). Prevalence was statistically higher for all other diabetes-
related complications in the DN group than in the control cohort
with heart disease being the most common in both groups (76%
for DN vs. 68% for controls). Controlling for comorbidities,
patients with 1 other diabetes-related complications had statis-
tically higher pharmacy and total medical charges for both DN
and controls. Charges were also higher for DN patients among
thosewith orwithout other diabetes-related complications.CON-
CLUSION: DN can occur in absence of other diabetes-related
complications. DN and other diabetes-related complications have
signiﬁcant impact on medical charges.
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OBJECTIVE: To identify factors associated with high health care
charges in patients diagnosed with diabetic neuropathy (DN).
METHODS: Data were extracted from a large, commercial
health plan database between July 2004 and June 2006. Patients
aged 18–64 were selected if they had a DN diagnosis (ICD9:
357.2x; 250.6x) between July 2004 and June 2005 (Year 1) and
were continuously enrolled over the study period. High (low)
charges groups were constructed for patients in the top and
bottom decile of annual charges. Comorbidities in Year 1 were
identiﬁed, and total charges in Year 2 (July 2005-June 2006)
were examined. Logistic regression was used to identify factors
associated with high charges. The factors considered were age,
gender, type of health plan, and other comorbidities. RESULTS:
A total of 8655 DN patients (mean age 51 years, 46% female)
were included in the study. Compared to the low charges group,
patients in the high charges group had signiﬁcantly more unique
number of co-morbid medical conditions (16 vs. 10) and higher
charges ($231,898 vs. $20,213) (both p < 0.001). The high
charges group contributed 56% of the total charges of all DN
patients. Factors signiﬁcantly (p < 0.001) contributing to high
charges included dialysis status (OR = 19.2),metastatic cancer
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